Cargando…

PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer

We aim to elucidate the prognostic value of PIK3CA mutations and copy number (CN) gain (PIK3CA-mut/gain) in hormone receptor-positive and HER2-negative (HR + /HER2−) breast cancer (BC). We analyzed primary HR + /HER2− BC from three publicly available datasets comprising over 2000 samples and assesse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Migliaccio, Ilenia, Paoli, Marta, Risi, Emanuela, Biagioni, Chiara, Biganzoli, Laura, Benelli, Matteo, Malorni, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857304/ https://www.ncbi.nlm.nih.gov/pubmed/35181669 http://dx.doi.org/10.1038/s41523-022-00382-5

Ejemplares similares

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2021)

Somatic mutation and gain of copy number of PIK3CA in human breast cancer
por: Wu, Guojun, et al.
Publicado: (2005)

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
por: Rossi, Lorenzo, et al.
Publicado: (2019)

An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
por: Risi, Emanuela, et al.
Publicado: (2019)

Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial
por: Galardi, Francesca, et al.
Publicado: (2021)

Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer
por: Vignoli, Alessia, et al.
Publicado: (2021)

Cell-Free DNA-Methylation-Based Methods and Applications in Oncology
por: Galardi, Francesca, et al.
Publicado: (2020)

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
por: Rossi, Lorenzo, et al.
Publicado: (2018)

PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer
por: Amato, Ottavia, et al.
Publicado: (2023)

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
por: McCartney, Amelia, et al.
Publicado: (2019)

Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy
por: Bonechi, Martina, et al.
Publicado: (2018)

Charting differentially methylated regions in cancer with Rocker-meth
por: Benelli, Matteo, et al.
Publicado: (2021)

Improved survival associated with somatic PIK3CA mutations in copy-number low endometrioid endometrial adenocarcinoma
por: LIN, DOUGLAS I.
Publicado: (2015)

Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
por: Guarducci, Cristina, et al.
Publicado: (2018)

Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly
por: Rios, Jonathan J., et al.
Publicado: (2013)

Cooperative oncogenic effect and cell signaling crosstalk of co-occurring HER2 and mutant PIK3CA in mammary epithelial cells
por: Dong, Lun, et al.
Publicado: (2017)

Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project
por: Peixoto, Ana, et al.
Publicado: (2023)

PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
por: Fusco, Nicola, et al.
Publicado: (2021)

PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy
por: Fidler, M J, et al.
Publicado: (2011)

Increased SOX2 Gene Copy Number Is Associated with FGFR1 and PIK3CA Gene Gain in Non-Small Cell Lung Cancer and Predicts Improved Survival in Early Stage Disease
por: Toschi, Luca, et al.
Publicado: (2014)

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
por: Hutchinson, Katherine E., et al.
Publicado: (2023)

Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
por: Migliaccio, Ilenia, et al.
Publicado: (2015)

Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells
por: Soh, Junichi, et al.
Publicado: (2009)

Risk assessment of disease recurrence in early breast cancer: A serum metabolomic study focused on elderly patients
por: Risi, Emanuela, et al.
Publicado: (2022)

ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data
por: Romagnoli, Dario, et al.
Publicado: (2018)

Copy Number Amplification of the PIK3CA Gene Is Associated with Poor Prognosis in Non-lymph node metastatic Head and Neck Squamous Cell Carcinoma
por: Suda, Toshihito, et al.
Publicado: (2012)

PIK3CA copy number aberration and activation of the PI3K-AKT-mTOR pathway in varied disease states of penile cancer
por: Adimonye, Anthony, et al.
Publicado: (2018)

Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment
por: Raphael, Ari, et al.
Publicado: (2022)

Carcinogenesis of PIK3CA
por: German, Sidra, et al.
Publicado: (2013)

Clinical impacts of genomic copy number gains at Xq28
por: Yamamoto, Toshiyuki, et al.
Publicado: (2014)

In situ single cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2(+) breast cancer
por: Janiszewska, Michalina, et al.
Publicado: (2015)

The role of abemaciclib in treatment of advanced breast cancer
por: McCartney, Amelia, et al.
Publicado: (2018)

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance
por: Módos, Orsolya, et al.
Publicado: (2016)

Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer
por: Avivar-Valderas, Alvaro, et al.
Publicado: (2018)

PIK3CA in Colorectal Cancer
por: Cathomas, Gieri
Publicado: (2014)

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
por: Cizkova, M, et al.
Publicado: (2013)

PIK3CA Mutation Is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients
por: Kim, Ju Won, et al.
Publicado: (2023)

Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
por: Vollbrecht, Claudia, et al.
Publicado: (2022)

Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer
por: Fiascarelli, Alessio, et al.
Publicado: (2023)

Allele-specific genomic data elucidate the role of somatic gain and copy-number neutral loss of heterozygosity in cancer
por: Ciani, Yari, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vbdch5g7tvbcqe5a9agijqfsk4